What is Crystagen studied for?

Crystagen is described as Glu-Asp-Pro, also called EDP, a synthetic three-amino-acid peptide from the Khavinson bioregulator family. The supplied evidence frames it as a research compound studied for immune, thymic, spleen, and immune-aging contexts rather than as an approved medicine.

How is Crystagen proposed to work?

The source attributes a hypothesis to the Khavinson group: EDP may influence lymphocyte proliferation and differentiation and may affect chromatin activity in aged immune cells through tissue-selective gene-expression effects. This remains a proposed model from the cited research context, not an independently settled mechanism.

Is Crystagen FDA approved?

No. The source lists Crystagen as not FDA approved. It is presented as preclinical research, with a separate note that it is approved in Russia as a supplement.

What side effects or safety limitations are reported?

The supplied source describes it as generally well tolerated but also states that safety data outside Russia are limited. The same side-effect section includes lack of FDA approval, which is regulatory context rather than an adverse event.

What dosing information is reported?

The source reports 10-20 mg daily, once or twice daily, with oral capsule or sublingual administration and 10-30 day cycles in one research-oriented row. These are source-reported research/community values and should not be read as personal medical instructions.

Bioregulators Preclinical - animal studies only

Crystagen

Also known as: Glu-Asp-Pro, EDP

At a glance

PeptiGuide dataset · reviewed Aug 2026

What it is

Short peptide bioregulator researched for immune and thymic aging models

Status

Preclinical

Evidence level: animal studies

Typical dose

10–20mg

Oral capsules or sublingual

Researched for

Immune system, spleen health, immune aging

Trial progress

PrePreclinical
IPhase I
IIPhase II
IIIPhase III
IVPhase IV
FDAFDA approved

Preclinical - Promising animal research, limited human data

Use the tools

In plain language

Crystagen is identified as Glu-Asp-Pro (EDP), a synthetic tripeptide in the Khavinson short- bioregulator family.
The source describes research interest in immune-system function, thymic regulation, spleen health, and immune aging.
Evidence is characterized as , with no registered human clinical trials reported in the supplied data.
Source-reported dosing is 10-20 mg daily, once or twice daily, using oral capsules or a sublingual route.

How it's thought to work

Crystagen is presented as a cytogen-class short . In the supplied source, the Khavinson group hypothesizes that EDP can influence lymphocyte proliferation and differentiation and may reactivate chromatin in aged immune cells, potentially relating to T-cell function through tissue-specific gene-expression regulation. The source explicitly treats this as a proposed epigenetic model supported by that group's work, not as independent scientific consensus.

What the research shows

Where the research stands

The supplied source characterizes the published evidence as mainly and ex vivo. It notes work on EDP-class peptides in PHA-stimulated lymphocytes from elderly donors, including reported chromatin-structure changes, and mentions lymphocyte activity findings in thymic explant and epithelial-cell models. A Russian clinical-observational report is described as commonly cited, but the source says it was not a registered randomized trial, so human efficacy should be treated as preliminary.

What it shows

✓ Animal studies

Promising animal research, limited human data

△ Limitations

Animal study doses may not translate directly to humans.

Bottom line: Preclinical research; reported as supplement-approved in Russia Not FDA approved

Typical dosing

CommunityCommunity dataset

10–20 mg

daily

10 mgfull range seen20 mg

Community-reported dosing for an immune-system bioregulator in the Khavinson short-peptide group; this is not established clinical guidance.

Research dosing

Animal studies onlyAnimal studies only - may not translate to humans

Doses observed in studies

10-20 mg daily

Animal study doses may not translate directly to humans.

Duration: 10-30 day cycles
Administration: Oral capsules or sublingual

Timing & administration

Best time to take

Morning on an empty stomach

Once or twice daily

Food recommendation

Take on an empty stomach

Why this timing?

The source gives a fasted-use rationale based on typical peptide-bioregulator absorption practices, but does not provide independent clinical validation for this timing rule.

Possible side effects

Not everyone experiences these. Individual responses vary with dose, duration, and personal factors.

Generally well tolerated
Limited safety data outside Russia
Not FDA approved

Not everyone experiences side effects, and severity can vary by context, purity, route, and individual health factors.

Sources

PubMed ClinicalTrials.gov FDA.gov

Frequently asked questions

Sequence

H-Glu-Asp-Pro-OH (EDP)

One open dataset

Every fact on this page - doses, side effects, references - comes from the same PeptiGuide dataset that powers the Tracker, Compare, and the Lab.

Browse the dataset

Save to my research list Get updates on Crystagen

Educational resource, not medical advice. Talk to your clinician before acting on anything here.

Community discussion

Comments are moderated before they appear. Keep it evidence-focused.

Crystagen

In plain languageIn plain language

How it's thought to workHow it's thought to work

What the research showsWhat the research shows

Typical dosing

Research dosing

Timing & administrationTiming & administration

Possible side effectsPossible side effects

SourcesSources

Frequently asked questionsFrequently asked questions